WO2013077542A1 - Composition comprising hovenia dulcis extract for treating or preventing intestinal disorders - Google Patents

Composition comprising hovenia dulcis extract for treating or preventing intestinal disorders Download PDF

Info

Publication number
WO2013077542A1
WO2013077542A1 PCT/KR2012/008138 KR2012008138W WO2013077542A1 WO 2013077542 A1 WO2013077542 A1 WO 2013077542A1 KR 2012008138 W KR2012008138 W KR 2012008138W WO 2013077542 A1 WO2013077542 A1 WO 2013077542A1
Authority
WO
WIPO (PCT)
Prior art keywords
constipation
composition
extract
present
treating
Prior art date
Application number
PCT/KR2012/008138
Other languages
French (fr)
Korean (ko)
Inventor
최철웅
설희진
반상오
장욱진
이규옥
김현
박가현
김희숙
이동욱
김선오
김재갑
Original Assignee
재단법인 전라남도생물산업진흥재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 전라남도생물산업진흥재단 filed Critical 재단법인 전라남도생물산업진흥재단
Publication of WO2013077542A1 publication Critical patent/WO2013077542A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition for treating or preventing bowel disease, specifically constipation.
  • Constipation has long been said to be the source of all illnesses, and the appetite and bloat are not only inflated, but also the excreted toxic stool toxins are absorbed into the intestine, which promotes skin aging and promotes headache, acne, and skin. Rashes, etc. appear, if constipation is severe causes of hemorrhoids, such as breakage of dentition and escape of hemorrhoids during defecation, and even colon cancer. As a result, constipation occurs in a country with a high cultural level. In particular, women and office workers suffer a lot from constipation.
  • Constipation is less than twice a week to see the stool is less than 35 g stool is due to lack of exercise or stress accumulate bowel movements, stool mobility is reduced. Constipation refers to a case in which the stool remains in the colon for more than a normal time. The stool is usually excreted 12 to 72 hours after the food is eaten, and the type of food ingested affects the bowel time. In other words, high fiber foods absorb liquid in the intestine to increase volume, make excreta, and excrete, whereas low fiber content is the opposite.
  • Constipation itself is not a disease but a symptom of headache, vision disorders and allergies caused by toxic gases (hydrogen sulfide, nitrosoamine, ammonia, phenol) due to abnormal intestinal fermentation caused by constipation
  • Active prevention and treatment are necessary because it causes various serious secondary diseases such as diseases (depression), skin diseases (acne, etc.), bad breath, colon diseases (hemorrhoids, colon cancer, etc.), arteriosclerosis, high blood pressure, stroke, and immunodeficiency.
  • constipation therapeutic agent that has a high effect of improving, treating or preventing intestinal diseases, including constipation, and lacking side effects, by improving intestinal activity among natural products that are expected to minimize the possibility of safety problems.
  • the present invention is to solve the problems of the prior art as described above, it is an object of the present invention to provide a composition for treating or preventing constipation comprising a bark extract as an active ingredient.
  • the present invention relates to a composition for treating or preventing intestinal diseases with the extract of Hovenia dulcis in order to achieve the above object.
  • the bark tree extract may be any one selected from the group consisting of water, alcohol having 1 to 5 carbon atoms and mixtures thereof with respect to the bark tree branch as an extraction solvent.
  • the barberry extract is a barberry extract obtained by fractionating any one selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, butanol water, and mixtures thereof in the barberry extract May be a fraction of.
  • the intestinal disease may be any one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea and altered bowel syndrome and irritable bowel syndrome, for example, may be constipation.
  • the constipation may be a functional constipation or a matrix constipation
  • the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation
  • the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon It may be a certificate.
  • the present invention also relates to a food composition for preventing or improving constipation comprising the extract of Hovenia dulcis as an active ingredient.
  • the present invention relates to the use of the extract of Hovenia dulcis , the use may be for the treatment or prevention of constipation or the use of improving or preventing constipation.
  • patient includes both humans and animals.
  • composition is meant to include a product comprising the specified ingredients in the specified amounts, as well as products resulting directly or indirectly from a combination of the specified ingredients in the specified amounts.
  • an effective amount or therapeutically effective amount means an amount of an extract or composition of the present invention effective to produce the desired therapeutic, alleviation, inhibitory or prophylactic effect.
  • the inventors of the present invention while researching the intestinal function improving component from a natural substance derived from a low side effect and easy to administer, in the animal model, the constipation-induced constipation experimental model and intestinal motility experiment model using the charcoal Inducing intestinal function and activating the mucous secretion in the intestine was confirmed to have an excellent effect on improving constipation, based on this, the present invention was completed.
  • the present invention relates to a composition for treating or preventing intestinal diseases, which comprises the extract of Hovenia dulcis as an active ingredient in order to achieve the above object.
  • the composition for treating or preventing bowel disease may be a pharmaceutical composition for treating or preventing constipation or a food composition for improving or preventing bowel disease.
  • the composition for treating or preventing bowel disease may be a composition having an effect of treating, improving or preventing bowel disease, for example, constipation.
  • the present invention relates to a composition for treating or preventing intestinal diseases, for example, constipation containing Hovenia dulcis extract as an active ingredient in order to achieve the above object.
  • the composition for treating or preventing constipation may be a pharmaceutical composition for treating or preventing constipation.
  • the hut tree extract may be a hydrothermal extract of hut tree branches.
  • Hovenia dulcis is a deciduous broad-leaved arboretum, a plant of the sea buckthorn family, also called the earth tree.
  • the height is 10 m to 17 m
  • the bark is black gray
  • the twigs are brownish purple.
  • Winter snow is covered with two snow scales and has hairs.
  • the leaves are 8 cm to 15 cm long, alternate, broad ovate or oval.
  • Three coarse leaf veins develop on the leaves and fine teeth on the edges. It is bisexual, with white flowers blooming in June to July. The flowers run in an inflorescence. Calyxes and petals are 5, and pistils are divided into 3 pieces.
  • Fruits from September to October are brown and look like chicken claws. Three seeds of fruit contain one seed each. Seeds are dark brown and glossy.
  • the bark extract may be prepared by adding a fractional solvent to the crude extract prepared by extracting or extracting with an extraction solvent.
  • the extraction solvent may be at least one selected from the group consisting of water and an organic solvent, for example, may be water.
  • the organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms such as methanol or ethanol, ethyl acetate or acetone, and a nonpolar solvent of ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof.
  • the alcohol having 1 to 5 carbon atoms may be an alcohol or an aqueous solution of alcohol, and specifically may be an aqueous alcohol solution having 1 to 5 carbon atoms such as 50 to 99% ethanol, and more specifically 1 to 5 carbon atoms such as 50 to 95% ethanol. 5 may be an aqueous solution of alcohol.
  • the extract of the present invention may be prepared according to a method for preparing an extract for a conventional plant, and specifically, may be cold extraction, hot extraction or thermal extraction, and a conventional extraction device, ultrasonic grinding extractor or fraction. Can be used.
  • the extract of the present invention may be a fraction further subjected to the fractionation process after adding a fractional solvent to the crude extract extracted with the solvent.
  • the fractional solvent may be a solvent selected from the group consisting of water, ethyl acetate, ether, chloroform, benzene, hexane, methylene chloride and mixed solvents thereof.
  • the prepared extract or the fraction obtained by performing the fractionation process can be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying.
  • the filtration may be using a filter paper or a reduced pressure filter
  • the concentration may be concentrated under reduced pressure using a reduced pressure concentrator, for example, a rotary evaporator
  • the drying may be carried out by freeze drying as an example.
  • the intestinal disease is a concept including all diseases caused by abnormal bowel activity, for example, one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea altered bowel syndrome and irritable bowel syndrome, for example, constipation.
  • the constipation may be a functional constipation or a matrix constipation
  • the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation
  • the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon May be
  • constipation refers to a case in which the stool is less than 35 g and the stool is less than twice a week, and when the lack of exercise or the stress accumulates, the bowel movement is lowered and the stool movement ability is lowered.
  • Constipation refers to a case in which the stool remains in the colon for more than a normal time, and the stool is usually excreted after 12 to 72 hours after the food is eaten. can do.
  • the type of food affects bowel time. In other words, high fiber foods absorb liquid in the intestine to increase volume, make excreta, and excrete, whereas low fiber content is the opposite.
  • a composition for treating or preventing constipation comprising the bark extract of the present invention as an active ingredient is 0.001% by weight to 99.99% by weight of the active ingredient, specifically the bark extract, preferably May comprise 0.1 wt% to 99 wt%.
  • the composition for treating or preventing constipation including the larvae extract, specifically, the foliar tree branched hydrothermal extract as an active ingredient does not cause problems of side effects in that it is an extract of natural substances, improving the intestinal motility Through the improvement or prevention effect of constipation through excellent has an excellent effect.
  • Bowel disease for example, the composition for treating or preventing constipation comprising the extract of the bark of the present invention as an active ingredient can be applied directly to humans.
  • the composition for the treatment or prevention of constipation containing the extract of the barn tree as an active ingredient comprises a material that has the effect of treating or preventing intestinal disease to the barn tree extract alone as an active ingredient It may be further included as an active ingredient, and may further include additional ingredients, pharmaceutically acceptable or nutritionally acceptable carriers, excipients, diluents or subcomponents, depending on the formulation, method of use, and purpose of use.
  • the composition for treating or preventing intestinal diseases for example, constipation, including the locust extract as an active ingredient, in addition to the active ingredient, nutrients, vitamins, electrolytes, flavors, coloring agents, neutralizing agents, pectic acid and Salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • the carrier, excipient or diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, ziitol, erythritol, maltitol, starch, acycia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline In the group consisting of cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, saline It may be one or more selected, but is not limited to any conventional carrier, excipient or diluent can be used.
  • the ingredients may be added independently or in combination with the active ingredient, namely liana.
  • the composition for the treatment or prevention of constipation comprising the extract of the bark as an active ingredient is 0.001% to 99.9% by weight, preferably 0.1% to 99% by weight, based on the total weight of the composition, More preferably, it may include 1% by weight to 50% by weight.
  • the content of the additional component is preferably added in the range of 0.1 to 20 parts by weight per 100 parts by weight of the composition for treating or preventing constipation.
  • constipation treatment or prevention composition containing the extract of the barn tree as an active ingredient, conventional fillers, extenders, binders, disintegrants, surfactants, anticoagulants, lubricants, wetting agents, It may further include fragrances, emulsifiers or preservatives, and may be used orally or parenterally.
  • solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate in the active ingredient, that is, liana. It is prepared by mixing (calcium carbonate), sucrose or sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • excipient such as starch, calcium carbonate in the active ingredient, that is, liana. It is prepared by mixing (calcium carbonate), sucrose or sucrose, lactose, gelatin and the like.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may include, for example, wetting agents, sweeteners, fragrances, and preservatives. have.
  • the formulation of the composition for treating or preventing intestinal diseases, for example, constipation, including the larvae extract of the present invention as an active ingredient may be in a preferred form according to the method of use, in particular, the rapid action of the active ingredient after administration to a mammal, Methods known in the art can be employed and formulated to provide sustained or delayed release.
  • formulations examples include granules, powders, syrups, solutions, suspensions, tablets, injections, spirits, cataplasma, capsules, soft or hard gelatin capsules, and the like.
  • compositions for treating or preventing intestinal diseases, such as constipation comprising the locust extract of the present invention as an active ingredient, can be prepared using Remington's Pharmaceutical Science (Recent edition) using appropriate methods known in the art. , Mack Publishing Company, Easton PA).
  • Dose of the bowel disease for example, the composition for the treatment or prevention of constipation, including the larvae extract according to the present invention as an active ingredient, considering the method of administration, the age, sex and weight of the recipient, and the severity of the disease, etc. Can be appropriately selected.
  • composition for the treatment or prevention of constipation comprising the extract of the bark of the present invention as an active ingredient, based on the active ingredient, 0.0001 mg / kg to 1000 mg / kg, in order to be more effective 0.01 mg / kg To 100 mg / kg.
  • Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • composition for treating or preventing intestinal diseases, for example constipation including the larvae extract of the present invention as an active ingredient, for a compound or natural product having a known intestinal disease, for example constipation treatment or prevention effect in addition to the active ingredient
  • the extract may further include, and may be included in 5 parts by weight to 200 parts by weight with respect to 100 parts by weight of the active ingredient.
  • the present invention relates to a food composition for preventing or improving intestinal diseases, for example, constipation containing Hovenia dulcis extract as an active ingredient to achieve the above object.
  • the hut tree may be a hut branch.
  • the hut tree extract may be a hydrothermal extract of hut tree branches.
  • the hut tree branch hydrothermal extract may be prepared by a method including a hot water extraction step added to the hut tree branch and extracted for 1 hour to 5 hours at 80 °C to 120 °C.
  • the term "food” means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through some processing process. It is intended to include all dietary supplements, beverages, food additives and beverage additives.
  • Examples of the food of the present invention include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
  • the food in the present invention includes special nutritional products (e.g., prepared oils, infants, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( For example, soy sauce, miso, red pepper paste, mixed soy sauce), sauces, confectionery (e.g. snacks), dairy products (e.g.
  • fermented milk cheese, etc.
  • other processed foods kimchi, pickles (various kimchi, pickles, etc.)
  • beverages examples include, but are not limited to, fruits, vegetable drinks, soy milk, fermented beverages, and the like, and natural seasonings (eg, ramen soup).
  • the food specifically, nutraceuticals, beverages, food additives and beverage additives may be prepared by conventional manufacturing methods.
  • a health functional food is a biological defense rhythm control, disease prevention and the like having a food group or a food composition which has added value to the food by using physical, biochemical, biotechnological techniques, etc. It refers to a food that is designed and processed to fully express the weight control function related to recovery.
  • the dietary supplement may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of dietary supplements.
  • the drink refers to a generic term for drinking to quench thirst or to enjoy the taste and is intended to include a functional beverage.
  • the beverage is not particularly limited to other ingredients other than including the hawthorn extract as an active ingredient in the indicated ratio as an active ingredient, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have.
  • natural carbohydrates examples include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
  • the ratio of the natural carbohydrate may generally be about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the food composition of the present invention.
  • the composition of the present invention may further contain a pulp for the production of natural fruit juices, fruit juice drinks, vegetable drinks.
  • the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
  • the health functional beverage is a biological defense rhythm control or disease prevention of a beverage group or beverage composition which has added value to the beverage by using physical, biochemical and biotechnological techniques to act and express the function of the beverage for a specific purpose.
  • the health functional beverage is not particularly limited to other ingredients except for containing the hawthorn extract of the present invention as an essential ingredient in the ratio indicated, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. .
  • natural carbohydrates examples include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and xylitol Sugar alcohols such as sorbitol and erythritol.
  • natural flavoring agents tacumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of said natural carbohydrates is generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention.
  • the active ingredient in the intestinal disease, for example, constipation prevention or improvement food composition
  • the active ingredient may comprise from 0.01% to 15% by weight of the total food weight
  • the beverage composition It may be included in a ratio of 0.02 g to 5 g, preferably 0.3 g to 1 g based on 100 ml.
  • the present invention also relates to the use of Hovenia dulcis extract in order to achieve the above object.
  • the use of the bark extract may be used for intestinal diseases, specifically for the treatment, improvement or prevention of intestinal diseases. Specifically, it may be used for treating or preventing constipation or improving or preventing constipation.
  • the intestinal disease is a meaning including all diseases caused by abnormal bowel activity, specifically, one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea altered bowel syndrome and irritable bowel syndrome, more specifically constipation.
  • the constipation may be a functional constipation or a matrix constipation
  • the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation
  • the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon May be
  • the bark extract may be prepared by adding a fractional solvent to the crude extract prepared by extracting or extracting with an extraction solvent.
  • the extraction solvent may be at least one selected from the group consisting of water and an organic solvent, for example, may be water.
  • the organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms such as methanol or ethanol, ethyl acetate or acetone, and a nonpolar solvent of ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof.
  • the alcohol having 1 to 5 carbon atoms may be an alcohol or an aqueous alcohol solution, and specifically, may be an aqueous alcohol solution having 1 to 5 carbon atoms such as 50% to 99% ethanol, and more specifically 50 to 95% carbon atoms such as ethanol. It may be 1 to 5 aqueous alcohol solution.
  • the bark extract of the present invention induces intestinal function activity in the animal model using charcoal, constipation-induced experimental model and intestinal motility experimental model, and activates the mucous secretion in the intestine, which is excellent for improving constipation.
  • it is derived from a natural substance that is a plant edible as a food, so it is less likely to cause side effects or toxicity problems. Therefore, the present invention is effective in improving intestinal function and intestinal diseases, specifically constipation, prevention and treatment. Since the present invention can be used as a safe and safe pharmaceutical composition or a functional food composition, the present invention can be used in various industries.
  • Figure 1 is a schematic diagram for preparing the extract and fractions of the bark tree extract according to an embodiment of the present invention.
  • Figure 2 is a graph showing the number of stool collected during the three days of sample administration to the constipation-induced constipation-derived animal model according to an embodiment of the present invention compared to the control.
  • Figure 3 is a graph showing the number of stool collected during the three days of sample administration to the constipation-induced constipation-derived animal extract according to an embodiment of the present invention as a percentage (%).
  • Figure 4 is a graph showing the weight of the stool collected during the three days of the administration of the sample in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention compared to the control.
  • Figure 5 is a graph showing the weight of the stool collected during the three days of sample administration in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention compared to the control group in percentage (Fig. 3b).
  • Figure 6 is a graph showing the water content of the stool collected for 3 days of sample administration compared to the control in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention.
  • FIG. 7 is a photograph showing the movement of activated charcoal meal (charcoal meal) in the intestine in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention.
  • Rf movement rate
  • FIGS. 9 and 10 are graphs promoting the contractile relaxation exercise of the colon at a concentration of 0.2 mg / mL of the extract of the barley branch according to an embodiment of the present invention as a control group (Fig. 9) and the bark tree extract administration group (Fig. 10) The graph shown.
  • hexane soluble fraction, the chloroform soluble fraction, the ethyl acetate soluble fraction and the butanol soluble fraction were concentrated under reduced pressure, and then freeze-dried to obtain hexane fraction 0.04 g, chloroform fraction 0.6 g, ethyl acetate fraction 2.2 g, butanol fraction 8 g, and water fraction 18.35 g. Was obtained and used as a sample.
  • Example 1 In order to measure the constipation therapeutic effect of the extract of the hut obtained in Example 1, the experiment was conducted using the method described in the literature using a rat model as follows (Mamoru kakino et al., Laxative effects of agarwood on low-fiber diet-induced constipation in rats.BMC Complementary and alternative Medicine.2010; 10:68).
  • Sprague-Dawley male rats of 4 weeks old (100 g to 200 g body weight) were purchased from Samtaco Co., Ltd. and used for experiments after being adapted to the environment for 1 week.
  • the breeding environment was a temperature of 20 °C to 22 °C humidity 50% to 55%, the contrast cycle was adjusted by 12 hours. Water and feed were freely provided.
  • the experimental animals were divided into five groups of five by using the ingot method, and were fed a normal diet as a normal group (Normal group) and a negative control group as a low fiber diet (LFD) intake group (hereinafter , LFD), Dulcolax (Dercolax; Boehringer Ingelheim), a positive control group (hereinafter referred to as LFD + dulcolax), HTH (200 mg / kg) treated group (hereinafter, LFD) + WEHD).
  • LFD low fiber diet
  • LFD + dulcolax a positive control group
  • HTH 200 mg / kg treated group
  • Low fiber diet was produced to cause constipation, the composition is as follows. It contains 9.0% of moisture, 21.9% of crude protein, 6.1% of crude fat, 0.1% of dietary fiber, 5.9% of crude starch, and 57.0% of soluble nitrogen. The composition is 41.5% of corn starch and 24.5% of milk casein. , 10.0% sucrose, 10.0% dextrin, 7.0% mineral mixture, 6.0% corn oil, 1.0% vitamin mixture.
  • the normal control group and the negative control group were orally administered distilled water, and the positive control group was osmolal drug dulcolax (dulcolax) at a concentration of 100 mg / kg
  • Experimental group was administered orally once a day with a hot water extract (WEHD) at a concentration of 200 mg / kg.
  • WEHD hot water extract
  • the stools of each experimental animal were collected daily for 3 days after the start of the experiment, and the number of stools and the weight of the stool (wet weight) were measured.
  • the sides were dried in an oven for 24 hours to determine the dry weight, and the difference between the side weight and the dry weight was calculated by dividing the side weight.
  • the effect of constipation treatment on the hot-water extract of the barley branch was observed.
  • the constipation-induced experimental animal model confirmed the therapeutic effect of the constipation of the extract of barley branch extract extracted in Example 1, the number, weight, and water content of each group compared to the negative control group, the results are shown in Figure 2 to 6 is shown.
  • the sides of each group was collected for 3 days, and the weight of the dry side was increased by 7.1% compared to the negative control group compared to the negative control group.
  • the group administered with the barley branch extract was confirmed to increase by 5% than the negative control group.
  • Activated charcoal meal transfer experiments were performed to evaluate the effects of bowel function and constipation.
  • Tortilla water extract (WEHD) was orally administered at a concentration of 200 mg / kg, and 1 hour later, 5% dissolved in 10% arabic gum (Sigma, USA) solution (0.2 ml / animal po) to the test animals.
  • Activated carbon (Sigma, USA) suspensions were administered. After 1 hour, the gastrointestinal tract was sacrificed, and the migration rate (Rf) in the intestinal distance from the duodenum to the ileum was examined, and is shown in FIGS. 7 and 8.
  • Activated carbon used in this experiment was produced by burning various organic materials (wood, etc.), and has a strong adsorption, nontoxicity, and no pharmacological effect.
  • Rats weighing 300 g to 350 g were sacrificed by CO 2 , the abdomen was incised and the ileum was isolated and separated, followed by Kreb's solution (111 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 2.0 mM CaCl 2 , 1.2 mM). 2 cm fragments were used in NaH 2 PO 4 , 25 mM NaHCO 3 , 11.5 mM glucose).
  • the ileal sections were suspended in an acrylic bath filled with Kreb's solution saturated with oxygen. The temperature in the acrylic bath was maintained at 37 ° C. and the pH of the solution was maintained at 7.4 by continuously supplying carbogen (95% O 2 and 5% CO 2 ) during the experiment.
  • the effect of the barley hot water extract on the basic tension of the extracted ileal section is that when the motility of the ileal section is stabilized and the tension is kept constant, the barley hot water extract is added at a concentration of 0.2 mg / mL to change the amplitude according to the tension change. It measured and the result is shown to FIG. 9 and FIG.
  • Vitamin B6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is a composition which is relatively suitable for the health functional food
  • the composition is mixed in a preferred embodiment, but the compounding ratio may be arbitrarily modified, and the above components are mixed according to a general health functional food manufacturing method.
  • the granules can then be prepared and used in the manufacture of nutraceuticals in accordance with conventional methods.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a composition comprising Hovenia dulcis extract as an active ingredient for the treatment or prevention of intestinal disorders. Particularly, in a constipation-inducing experimental model, and in an intestinal motility test model, Hovenia dulcis, an active ingredient of the present invention, induced the activation of intestinal function and alleviated constipation by activating the secretion of mucus in the intestine of an animal model by using charcoal. Further, since Hovenia dulcis is derived from a natural substance, side effects or toxic problems are less likely to occur. Therefore, the present invention provides a pharmaceutical composition or functional food composition which improves intestinal function and alleviates intestinal disorders, and which is especially effective and safe in the prevention and treatment of constipation.

Description

헛개나무 추출물을 포함하는 장 질환 치료 또는 예방용 조성물Composition for the treatment or prevention of bowel disease, including the extract
본 발명은 장 질환, 구체적으로 변비 치료 또는 예방용 조성물에 관한 것이다.The present invention relates to a composition for treating or preventing bowel disease, specifically constipation.
근래의 식생활은 생활 수준의 급속한 향상으로 인해 고지방과 고단백질이 함유된 육류와 인스턴트 식품 등의 고칼로리를 가지는 식품의 섭취가 증가된 반면에 야채나 섬유질을 함유하는 식품의 섭취가 감소됨으로써, 성인병과 비만 환자가 날로 증가되고 있는 추세에 있음은 잘 알려진 사실이다.In recent years, the diet has increased intake of high-calorie and high-protein meats and foods containing high-calorie foods, such as fast foods, while reducing the intake of foods containing vegetables and fiber, It is well known that overweight obese patients are on the rise.
변비는 예로부터 만병의 근원으로 일컬어지고 있으며, 식욕이 없고 늘 복부가 팽만한 상태에 있을 뿐 아니라 배설되지 못한 변의 독소가 장으로 흡수되어 혈액에 흡수됨으로써, 피부노화를 촉진시키고 두통이나 여드름, 피부 발진 등이 나타나며, 변비가 심하면 배변 시 치열의 파손과 치핵의 탈출 등 치질의 원인이 되고, 심하면 대장암까지 발생된다. 이와 같이 변비는 문화수준이 높은 나라에서 많이 발생하게 되는데, 특히 직장여성이나 사무직 종사자들이 변비로 인해 많은 고통을 받고 있다.Constipation has long been said to be the source of all illnesses, and the appetite and bloat are not only inflated, but also the excreted toxic stool toxins are absorbed into the intestine, which promotes skin aging and promotes headache, acne, and skin. Rashes, etc. appear, if constipation is severe causes of hemorrhoids, such as breakage of dentition and escape of hemorrhoids during defecation, and even colon cancer. As a result, constipation occurs in a country with a high cultural level. In particular, women and office workers suffer a lot from constipation.
변비(Constipation)는 1주일에 2회 이하 변을 보며 대변량이 35 g 이하인 경우를 말하는 것으로 운동 부족이나 스트레스가 누적되면 장관운동이 저하되고, 변의 이동 능력이 떨어지기 때문이다. 변비증(Constipation)은 결장 안에 대변이 보통 시간 이상 머물러 있는 경우를 말하는 것으로서, 대변은 음식을 섭취하고 보통 12 내지 72시간 후에 배설되는데, 섭취하는 음식의 형태는 배변시간에 영향을 준다. 즉, 섬유질이 많은 음식은 장에서 액체를 흡수하여 부피를 증가하고 배설물을 만들며 배설을 할 수 있게 자극을 주는 데 반하여 섬유질 함량이 적은 것은 이와 반대의 현상을 일으킨다. 변비 자체는 병이 아닌 증상이라고 할 수 있으나, 변비로 인한 장내 이상 발효로 생긴 유독가스 (황화수소, 니트로소아민, 암모니아, 페놀) 등으로 인한 두통, 시력장애, 알레르기의 원인이 되고, 복통, 정신질환 (우울증), 피부질환(여드름 등), 구취, 대장 질환(치질, 대장암 등), 동맥경화, 고혈압, 뇌졸중, 면역결핍 등 다양하고 심각한 2차 질환의 원인이 되므로 적극적인 예방과 치료가 필요하다.Constipation (constipation) is less than twice a week to see the stool is less than 35 g stool is due to lack of exercise or stress accumulate bowel movements, stool mobility is reduced. Constipation refers to a case in which the stool remains in the colon for more than a normal time. The stool is usually excreted 12 to 72 hours after the food is eaten, and the type of food ingested affects the bowel time. In other words, high fiber foods absorb liquid in the intestine to increase volume, make excreta, and excrete, whereas low fiber content is the opposite. Constipation itself is not a disease but a symptom of headache, vision disorders and allergies caused by toxic gases (hydrogen sulfide, nitrosoamine, ammonia, phenol) due to abnormal intestinal fermentation caused by constipation Active prevention and treatment are necessary because it causes various serious secondary diseases such as diseases (depression), skin diseases (acne, etc.), bad breath, colon diseases (hemorrhoids, colon cancer, etc.), arteriosclerosis, high blood pressure, stroke, and immunodeficiency. Do.
변비를 개선시키고 장기능을 원활히 하는 요법으로 식이섬유, 수분섭취, 운동 등이 모든 변비에 대한 치료 요법의 기본으로 시도되고 있으며, 이차적으로 사용되는 변비치료약물로서 하제는 그 효과가 일시적이고 종류에 따라서 여러 가지 부작용을 유발한다. 특히, 자극성 하제의 경우 장기 연용시 그 효력이 점차 감소되고, 더우기 장기복용시 장근신경총이 파괴되어 하제형 대장이 되어 대장기능을 상실할 수도 있다.In order to improve constipation and smooth bowel function, dietary fiber, water intake, exercise, etc. have been attempted as the basis for the treatment of all constipation. Therefore, it causes various side effects. In particular, in the case of irritation laxative effect is gradually reduced during long-term use, moreover, in the long-term use may be the bowel nerve plexus is destroyed to become a laxative type colon and lose colon function.
보통 한방약이나 생약성분은 부작용이 없다고 인식되고 있으나, 현재 사용하고 있는 한방 하제는 대부분 센나, 대황 등의 안트라퀴논 유도체 성분이 함유된 약재를 사용하고 있는데, 이는 자극성 하제에 속하여 매일 복용하거나 특히 임신 중에는 복용 금기이다.Although herbal medicines and herbal medicines are generally recognized as having no side effects, most herbal laxatives in use currently contain medicinal herbs containing anthraquinone derivatives such as senna and rhubarb, which are irritant laxatives taken daily or especially during pregnancy. Taking is contraindicated.
변비를 해소하기 위한 기능성 식품소재 중 가장 일반적인 것이 식이섬유이고 이외에도 다시마, 야콘, 삼백초, 결명자차, 동규자차, 알로에, 해조류 등을 포함하는 다양한 식품이 판매되고 있으나, 과학적으로 그 효과가 충분히 입증되었는가에 의문시되고 있다.The most common functional foods for relieving constipation are dietary fiber, and various foods including kelp, yacon, three hundred scents, unidentified tea, Donggyuja tea, aloe, and seaweed are sold. Is being questioned.
따라서, 상대적으로 안전성에 대한 문제가 발생할 가능성을 최소화할 수 있을 것으로 기대되는 천연물 중에서 장 활동 개선을 통하여 변비를 포함한 장 질환 개선, 치료 또는 예방 효과는 높고 부작용은 미비한 변비 치료제의 개발이 요구되고 있다.Therefore, it is required to develop a constipation therapeutic agent that has a high effect of improving, treating or preventing intestinal diseases, including constipation, and lacking side effects, by improving intestinal activity among natural products that are expected to minimize the possibility of safety problems. .
본 발명은 상기와 같은 종래기술의 문제점을 해결하기 위한 것으로서, 본 발명은 헛개나무 추출물을 유효성분으로 포함하는 변비 치료 또는 예방용 조성물을 제공하는 것을 목적으로 한다.The present invention is to solve the problems of the prior art as described above, it is an object of the present invention to provide a composition for treating or preventing constipation comprising a bark extract as an active ingredient.
본 발명은 상기 목적을 달성하기 위하여, 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 장 질환 치료 또는 예방용 조성물에 관한 것이다.The present invention relates to a composition for treating or preventing intestinal diseases with the extract of Hovenia dulcis in order to achieve the above object.
상기 헛개나무 추출물은 헛개나무 가지에 대해 물, 탄소수 1 내지 5의 알코올 및 이들의 혼합물로 이루어진 군 중에서 선택된 어느 하나를 추출용매로 추출한 것일 수 있다. 또한, 상기 헛개나무 추출물은 상기 헛개나무 가지 추출물에 헥산, 메틸렌클로라이드, 아세톤, 에틸아세테이트, 에틸에테르, 클로로포름, 부탄올 물 및 이들의 혼합물로 이루어진 군으로부터 선택된 어느 하나를 분획용매로 분획한 헛개나무 추출물의 분획물일 수 있다.The bark tree extract may be any one selected from the group consisting of water, alcohol having 1 to 5 carbon atoms and mixtures thereof with respect to the bark tree branch as an extraction solvent. In addition, the barberry extract is a barberry extract obtained by fractionating any one selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, butanol water, and mixtures thereof in the barberry extract May be a fraction of.
또한, 상기 장 질환은 변비, 설사, 게실염, 설사변비교대증 및 과민성 대장증후군으로 이루어진 군 중에서 선택된 어느 하나일 수 있고, 일 예로 변비일 수 있다.In addition, the intestinal disease may be any one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea and altered bowel syndrome and irritable bowel syndrome, for example, may be constipation.
상기 변비는 기능성 변비 또는 기질성 변비일 수 있고, 상기 기능성 변비는 이완성 변비, 경련성 변비 또는 배변 장애성 변비일 수 있으며, 상기 기질성 변비는 기능성 변비 장관의 협착, 긴 S상 결장증 또는 거대 결장증일 수 있다.The constipation may be a functional constipation or a matrix constipation, the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation, the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon It may be a certificate.
또한, 본 발명은 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 변비 예방 또는 개선용 식품 조성물에 관한 것이다.The present invention also relates to a food composition for preventing or improving constipation comprising the extract of Hovenia dulcis as an active ingredient.
또한, 본 발명은 헛개나무(Hovenia dulcis) 추출물의 용도에 관한 것으로, 상기 용도는 변비 치료 또는 예방용 용도나 변비 개선 또는 예방용 용도일 수 있다.In addition, the present invention relates to the use of the extract of Hovenia dulcis , the use may be for the treatment or prevention of constipation or the use of improving or preventing constipation.
본 명세서에서 특별한 언급이 없는 한, 환자란 사람 및 동물을 모두 포함하는 의미이다. Unless specifically stated herein, the term patient includes both humans and animals.
본 명세서에서 특별한 언급이 없는 한, 조성물이란 명시된 성분들을 명시된 양으로 포함하는 생성물뿐만 아니라, 명시된 양의 명시된 성분들의 배합물로부터 직접 또는 간접적으로 야기되는 생성물을 포함하는 의미이다.Unless stated otherwise in the specification, a composition is meant to include a product comprising the specified ingredients in the specified amounts, as well as products resulting directly or indirectly from a combination of the specified ingredients in the specified amounts.
본 명세서에서 특별한 언급이 없는 한, 유효량 또는 치료학적 유효량이란 목적하는 치료, 경감, 억제 또는 예방 효과를 발생시키는데 효과적인 본 발명의 추출물 또는 조성물의 양을 의미한다.Unless otherwise specified herein, an effective amount or therapeutically effective amount means an amount of an extract or composition of the present invention effective to produce the desired therapeutic, alleviation, inhibitory or prophylactic effect.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 발명자들은 부작용이 적고 투약이 쉬운 천연물질 유래 물질로부터 장 기능 개선 성분을 연구하던 중, 헛개나무 열수 추출물이 활성탄(charcoal)을 이용한 동물 모델, 변비유발 실험모델 및 장 운동능력 실험모델에서 장기능 활성을 유도하고, 장내의 점액 분비를 활성화하여 변비 개선에 탁월한 효과를 가지는 것을 확인하여, 이를 토대로 본 발명을 완성하게 되었다.The inventors of the present invention, while researching the intestinal function improving component from a natural substance derived from a low side effect and easy to administer, in the animal model, the constipation-induced constipation experimental model and intestinal motility experiment model using the charcoal Inducing intestinal function and activating the mucous secretion in the intestine was confirmed to have an excellent effect on improving constipation, based on this, the present invention was completed.
본 발명은 상기 목적을 달성하기 위하여, 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 장 질환 치료 또는 예방용 조성물에 관한 것이다.The present invention relates to a composition for treating or preventing intestinal diseases, which comprises the extract of Hovenia dulcis as an active ingredient in order to achieve the above object.
상기 장 질환 치료 또는 예방용 조성물은 변비 치료 또는 예방용 의약 조성물 또는 장 질환 개선 또는 예방용 식품 조성물일 수 있다. 상기 장 질환 치료 또는 예방용 조성물은 장 질환, 일 예로 변비의 치료, 개선 또는 예방 효과가 있는 조성물일 수 있다.The composition for treating or preventing bowel disease may be a pharmaceutical composition for treating or preventing constipation or a food composition for improving or preventing bowel disease. The composition for treating or preventing bowel disease may be a composition having an effect of treating, improving or preventing bowel disease, for example, constipation.
또한, 본 발명은 상기 목적을 달성하기 위하여, 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물에 관한 것이다. 상기 변비 치료 또는 예방용 조성물은 변비 치료 또는 예방용 의약 조성물일 수 있다. 상기 헛개나무 추출물은 헛개나무 가지의 열수 추출물일 수 있다.In addition, the present invention relates to a composition for treating or preventing intestinal diseases, for example, constipation containing Hovenia dulcis extract as an active ingredient in order to achieve the above object. The composition for treating or preventing constipation may be a pharmaceutical composition for treating or preventing constipation. The hut tree extract may be a hydrothermal extract of hut tree branches.
본 발명에 있어서, 헛개나무(Hovenia dulcis)는 낙엽활엽교목으로, 갈매나무과의 식물이며, 지구자나무라고도 한다. 높이 10 m 내지 17 m이고, 수피는 흑회색이며, 작은가지는 갈자색으로 피목 있다. 겨울눈은 2개의 눈비늘로 싸여 있으며 털이 있다. 잎은 길이 8 cm 내지 15 cm이며, 어긋나고 넓은 난형 또는 타원형이다. 잎에 3개의 굵은 잎맥이 발달하고 가장자리에 잔톱니가 있다. 자웅동주로 6월 내지 7월에 흰색 꽃이 피는데 양성화이다. 꽃은 취산꽃차례로 달린다. 꽃받침조각과 꽃잎은 5개씩이고, 암술대는 3개로 갈라진다. 9월 내지 10월에 얻을 수 있는 열매는 갈색이 돌고, 닭의 발톱 모양이다. 열매의 3실에 각각 1개씩의 종자가 들어 있다. 종자는 다갈색이고 윤기가 있다. In the present invention, Hovenia dulcis is a deciduous broad-leaved arboretum, a plant of the sea buckthorn family, also called the earth tree. The height is 10 m to 17 m, the bark is black gray, and the twigs are brownish purple. Winter snow is covered with two snow scales and has hairs. The leaves are 8 cm to 15 cm long, alternate, broad ovate or oval. Three coarse leaf veins develop on the leaves and fine teeth on the edges. It is bisexual, with white flowers blooming in June to July. The flowers run in an inflorescence. Calyxes and petals are 5, and pistils are divided into 3 pieces. Fruits from September to October are brown and look like chicken claws. Three seeds of fruit contain one seed each. Seeds are dark brown and glossy.
상기 헛개나무 추출물은 추출용매로 추출하거나 추출용매로 추출하여 제조한 조추출물에 분획용매를 가하여 분획하여 제조할 수 있다.The bark extract may be prepared by adding a fractional solvent to the crude extract prepared by extracting or extracting with an extraction solvent.
상기 추출용매는 물 및 유기용매로 이루어진 군에서 선택된 1종 이상일 수 있고, 일 예로 물일 수 있다. 상기 유기용매는 메탄올, 에탄올 등의 탄소수 1 내지 5의 알코올, 에틸아세테이트 또는 아세톤 등의 극성용매와 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄의 비극성용매 또는 이들의 혼합용매일 수 있다.The extraction solvent may be at least one selected from the group consisting of water and an organic solvent, for example, may be water. The organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms such as methanol or ethanol, ethyl acetate or acetone, and a nonpolar solvent of ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof.
상기 탄소수 1 내지 5의 알코올은 알코올 또는 알코올 수용액일 수 있고, 구체적으로 50 내지 99%의 에탄올 등의 탄소수 1 내지 5의 알코올 수용액일 수 있으며, 더욱 구체적으로 50 내지 95% 에탄올 등의 탄소수 1 내지 5의 알코올 수용액일 수 있다.The alcohol having 1 to 5 carbon atoms may be an alcohol or an aqueous solution of alcohol, and specifically may be an aqueous alcohol solution having 1 to 5 carbon atoms such as 50 to 99% ethanol, and more specifically 1 to 5 carbon atoms such as 50 to 95% ethanol. 5 may be an aqueous solution of alcohol.
본 발명의 추출물은 통상의 식물을 추출대상으로 한 추출물의 제조방법에 따라 제조된 것일 수 있으며, 구체적으로는 냉침추출법, 온침추출법 또는 열 추출법 등일 수 있으며, 통상의 추출기기, 초음파분쇄 추출기 또는 분획기를 이용할 수 있다.The extract of the present invention may be prepared according to a method for preparing an extract for a conventional plant, and specifically, may be cold extraction, hot extraction or thermal extraction, and a conventional extraction device, ultrasonic grinding extractor or fraction. Can be used.
또한, 본 발명의 추출물은 상기 용매로 추출한 조추출물에 대하여 분획용매를 가한 후, 분획과정을 더욱 실시한 분획물일 수 있다. 상기 분획용매는 물, 에틸아세테이트, 에테르, 클로로포름, 벤젠, 헥산, 메틸렌클로라이드 및 이들의 혼합용매로 이루어진 군에서 선택된 용매일 수 있다.In addition, the extract of the present invention may be a fraction further subjected to the fractionation process after adding a fractional solvent to the crude extract extracted with the solvent. The fractional solvent may be a solvent selected from the group consisting of water, ethyl acetate, ether, chloroform, benzene, hexane, methylene chloride and mixed solvents thereof.
상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물은 이후 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 여과, 농축 및 건조를 모두 수행할 수 있다.The prepared extract or the fraction obtained by performing the fractionation process can be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying.
구체적으로, 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있으며, 상기 농축은 감압 농축기, 일 예로 회전 증발기를 이용하여 감압 농축할 수 있으며, 상기 건조는 일 예로 동결건조법으로 수행할 수 있다.Specifically, the filtration may be using a filter paper or a reduced pressure filter, the concentration may be concentrated under reduced pressure using a reduced pressure concentrator, for example, a rotary evaporator, the drying may be carried out by freeze drying as an example.
상기 장 질환은 장 활동 이상에 의해 발생되는 모든 질환을 포함하는 개념으로, 일 예로 변비, 설사, 게실염, 설사변비교대증 및 과민성 대장증후군으로 이루어진 군 중에서 선택된 어느 하나, 일 예로 변비일 수 있다.The intestinal disease is a concept including all diseases caused by abnormal bowel activity, for example, one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea altered bowel syndrome and irritable bowel syndrome, for example, constipation.
상기 변비는 기능성 변비 또는 기질성 변비일 수 있고, 상기 기능성 변비는 이완성 변비, 경련성 변비 또는 배변 장애성 변비일 수 있으며, 상기 기질성 변비는 기능성 변비 장관의 협착, 긴 S상 결장증 또는 거대 결장증일 수 있다The constipation may be a functional constipation or a matrix constipation, the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation, the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon May be
본 발명에 있어서, 변비(Constipation)는 1주일에 2회 이하 변을 보며 대변량이 35g 이하인 경우를 말하는 것으로, 운동 부족이나 스트레스가 누적되면 장관운동이 저하되고, 변의 이동 능력이 떨어지기 발생된다.In the present invention, constipation refers to a case in which the stool is less than 35 g and the stool is less than twice a week, and when the lack of exercise or the stress accumulates, the bowel movement is lowered and the stool movement ability is lowered.
변비증(Constipation)은 결장 안에 대변이 보통 시간 이상 머물러 있는 경우를 말하는 것으로서, 대변은 음식을 섭취하고 보통 12시간 내지 72시간 후에 배설되는데, 섭취된 음식이 72시간 이상으로 장에 머물게 되는 경우 변비증이라 할 수 있다. 상기 음식의 형태는 배변시간에 영향을 준다. 즉, 섬유질이 많은 음식은 장에서 액체를 흡수하여 부피를 증가하고 배설물을 만들며 배설을 할 수 있게 자극을 주는 데 반하여 섬유질 함량이 적은 것은 이와 반대의 현상을 일으킨다.Constipation refers to a case in which the stool remains in the colon for more than a normal time, and the stool is usually excreted after 12 to 72 hours after the food is eaten. can do. The type of food affects bowel time. In other words, high fiber foods absorb liquid in the intestine to increase volume, make excreta, and excrete, whereas low fiber content is the opposite.
본 발명의 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 조성물 총 중량에 대하여 상기 유효성분, 구체적으로 상기 헛개나무 추출물을 0.001 중량% 내지 99.99 중량%, 바람직하게는 0.1 중량% 내지 99 중량%로 포함할 수 있다.Intestinal disease, for example, a composition for treating or preventing constipation, comprising the bark extract of the present invention as an active ingredient is 0.001% by weight to 99.99% by weight of the active ingredient, specifically the bark extract, preferably May comprise 0.1 wt% to 99 wt%.
상기 헛개나무 추출물, 구체적으로 상기 헛개나무 가지 열수 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 천연물질의 추출물이라는 점에서 부작용의 문제가 발생되지 아니하고, 장 운동능 향상을 통한 변비의 개선 또는 예방 효과가 뛰어나다는 점에서 우수한 효과를 가진다.Intestinal diseases, for example, the composition for treating or preventing constipation, including the larvae extract, specifically, the foliar tree branched hydrothermal extract as an active ingredient does not cause problems of side effects in that it is an extract of natural substances, improving the intestinal motility Through the improvement or prevention effect of constipation through excellent has an excellent effect.
본 발명의 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 인간에 직접 적용될 수 있다.Bowel disease, for example, the composition for treating or preventing constipation comprising the extract of the bark of the present invention as an active ingredient can be applied directly to humans.
상기 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 상기 헛개나무 추출물을 유효성분으로 단독으로 포함하거나 상기 헛개나무 추출물에 장 질환 치료 또는 예방용 효과가 있는 물질을 유효성분으로 더욱 포함할 수 있고, 이외 제형, 사용방법 및 사용목적에 따라 추가성분 즉, 약제학적으로 허용되거나 영양학적으로 허용되는 담체, 부형제, 희석제 또는 부성분을 추가로 포함할 수 있다. Intestinal diseases, for example, the composition for the treatment or prevention of constipation containing the extract of the barn tree as an active ingredient comprises a material that has the effect of treating or preventing intestinal disease to the barn tree extract alone as an active ingredient It may be further included as an active ingredient, and may further include additional ingredients, pharmaceutically acceptable or nutritionally acceptable carriers, excipients, diluents or subcomponents, depending on the formulation, method of use, and purpose of use.
보다 상세하게는, 상기 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 상기 유효성분 외에 추가로 영양제, 비타민, 전해질, 풍미제, 착색제, 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다.More specifically, the composition for treating or preventing intestinal diseases, for example, constipation, including the locust extract as an active ingredient, in addition to the active ingredient, nutrients, vitamins, electrolytes, flavors, coloring agents, neutralizing agents, pectic acid and Salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
또한, 상기 담체, 부형제 또는 희석제는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자이리톨, 에리스리톨, 말티톨, 전분, 아키시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀루로오스, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유, 덱스트린, 칼슘카보네이드, 프로필렌글리콜, 리퀴드 파라핀, 생리식염수로 이루어진 군에서 선택된 1이상 일 수 있으나, 이에 한정되는 것은 아니며 통상의 담체, 부형제 또는 희석제 모두 사용가능하다.In addition, the carrier, excipient or diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, ziitol, erythritol, maltitol, starch, acycia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline In the group consisting of cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, saline It may be one or more selected, but is not limited to any conventional carrier, excipient or diluent can be used.
상기 성분들은 상기 유효성분 즉, 헛개나무 추출물에 독립적으로 또는 조합하여 추가될 수 있다.The ingredients may be added independently or in combination with the active ingredient, namely liana.
상기 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 조성물 총 중량에 대하여 상기 유효성분을 0.001 중량% 내지 99.9 중량%, 바람직하게는 0.1 중량% 내지 99 중량%, 더욱 바람직하게는 1중량% 내지 50 중량% 포함할 수 있다. 또한, 상기 추가성분의 함량은 바람직하게는 상기 변비 치료 또는 예방용 조성물 100 중량부 당 0.1 중량부 내지 20 중량부 범위에서 추가할 수 있다.Intestinal diseases, for example, the composition for the treatment or prevention of constipation comprising the extract of the bark as an active ingredient is 0.001% to 99.9% by weight, preferably 0.1% to 99% by weight, based on the total weight of the composition, More preferably, it may include 1% by weight to 50% by weight. In addition, the content of the additional component is preferably added in the range of 0.1 to 20 parts by weight per 100 parts by weight of the composition for treating or preventing constipation.
또한, 상기 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물을 약제화하는 경우, 통상의 충진제, 증량제, 결합제, 붕해제, 계면활성제, 항응집제, 윤활제, 습윤제, 향료, 유화제 또는 방부제 등을 더욱 포함할 수 있으며, 경구 또는 비경구 모두 사용할 수 있다. In addition, in the case of pharmaceutical composition of the bowel disease, for example, constipation treatment or prevention composition containing the extract of the barn tree as an active ingredient, conventional fillers, extenders, binders, disintegrants, surfactants, anticoagulants, lubricants, wetting agents, It may further include fragrances, emulsifiers or preservatives, and may be used orally or parenterally.
구체적으로, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 유효성분 즉, 헛개나무 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다.Specifically, solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate in the active ingredient, that is, liana. It is prepared by mixing (calcium carbonate), sucrose or sucrose, lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.In addition to the commonly used simple diluents, water and liquid paraffin, various excipients may include, for example, wetting agents, sweeteners, fragrances, and preservatives. have.
또한, 본 발명의 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물의 제형은 사용방법에 따라 바람직한 형태일 수 있으며, 특히 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 채택하여 제형화할 수 있다.In addition, the formulation of the composition for treating or preventing intestinal diseases, for example, constipation, including the larvae extract of the present invention as an active ingredient may be in a preferred form according to the method of use, in particular, the rapid action of the active ingredient after administration to a mammal, Methods known in the art can be employed and formulated to provide sustained or delayed release.
구체적인 제형의 예로는 과립제, 산제, 시럽제, 액제, 현탁제, 정제, 주사제, 주정제, 카타플라스마제(cataplasma), 캅셀제, 연질 또는 경질 젤라틴 캅셀 등이 있다.Examples of specific formulations include granules, powders, syrups, solutions, suspensions, tablets, injections, spirits, cataplasma, capsules, soft or hard gelatin capsules, and the like.
더 나아가, 본 발명의 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은 당해 기술 분야의 공지된 적절한 방법을 사용하여 또는 레밍턴의 문헌(Remington's Pharmaceutical Science(최근판), Mack Publishing Company, Easton PA)에 개시되어 있는 방법을 이용하여 바람직하게 제형화될 수 있다.Furthermore, a composition for treating or preventing intestinal diseases, such as constipation, comprising the locust extract of the present invention as an active ingredient, can be prepared using Remington's Pharmaceutical Science (Recent edition) using appropriate methods known in the art. , Mack Publishing Company, Easton PA).
본 발명에 따른 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물의 투여량은, 투여방법, 복용자의 연령, 성별 및 체중, 및 질환의 중증도 등을 고려하여 당업자에 의해 적절하게 선택될 수 있다.Dose of the bowel disease, for example, the composition for the treatment or prevention of constipation, including the larvae extract according to the present invention as an active ingredient, considering the method of administration, the age, sex and weight of the recipient, and the severity of the disease, etc. Can be appropriately selected.
일 예로, 본 발명의 헛개나무 추출물을 유효성분으로 포함하는 변비 치료 또는 예방용 조성물은 상기 유효성분을 기준으로 할 때, 0.0001 mg/kg 내지 1000 mg/kg으로, 보다 효과적이기 위해서는 0.01 mg/kg 내지 100 mg/kg으로 투여할 수 있다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. As an example, the composition for the treatment or prevention of constipation comprising the extract of the bark of the present invention as an active ingredient, based on the active ingredient, 0.0001 mg / kg to 1000 mg / kg, in order to be more effective 0.01 mg / kg To 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
또한, 본 발명의 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 치료 또는 예방용 조성물은, 상기 유효성분 이외에 공지의 장 질환, 일 예로 변비 치료 또는 예방 효과를 갖는 화합물 또는 천연물에 대한 추출물을 더욱 포함할 수 있으며, 상기 유효성분 100 중량부에 대하여 각각 5 중량부 내지 200 중량부로 포함될 수 있다.In addition, the composition for treating or preventing intestinal diseases, for example constipation, including the larvae extract of the present invention as an active ingredient, for a compound or natural product having a known intestinal disease, for example constipation treatment or prevention effect in addition to the active ingredient The extract may further include, and may be included in 5 parts by weight to 200 parts by weight with respect to 100 parts by weight of the active ingredient.
또한, 본 발명은 상기 목적을 달성하기 위하여 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 예방 또는 개선용 식품 조성물에 관한 것이다.In addition, the present invention relates to a food composition for preventing or improving intestinal diseases, for example, constipation containing Hovenia dulcis extract as an active ingredient to achieve the above object.
상기 헛개나무는 헛개나무 가지일 수 있다. 상기 헛개나무 추출물은 헛개나무 가지의 열수 추출물일 수 있다. 상기 헛개나무 가지 열수 추출물은 헛개나무 가지에 첨가하고 80℃ 내지 120℃에서 1시간 내지 5시간 동안 추출하는 열수추출단계를 포함하는 방법으로 제조될 수 있다.The hut tree may be a hut branch. The hut tree extract may be a hydrothermal extract of hut tree branches. The hut tree branch hydrothermal extract may be prepared by a method including a hot water extraction step added to the hut tree branch and extracted for 1 hour to 5 hours at 80 ℃ to 120 ℃.
본 명세서에서 식품이란 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 건강기능식품, 음료, 식품 첨가제 및 음료 첨가제 등을 모두 포함하는 의도이다.In the present specification, the term "food" means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through some processing process. It is intended to include all dietary supplements, beverages, food additives and beverage additives.
본 발명의 식품은 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실,채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등)을 포함하나 이에 한정되지 않는다.Examples of the food of the present invention include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. In addition, the food in the present invention includes special nutritional products (e.g., prepared oils, infants, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( For example, soy sauce, miso, red pepper paste, mixed soy sauce), sauces, confectionery (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruits, vegetable drinks, soy milk, fermented beverages, and the like, and natural seasonings (eg, ramen soup).
상기 식품, 구체적으로 건강기능식품, 음료, 식품 첨가제 및 음료 첨가제는 통상의 제조방법으로 제조될 수 있다. The food, specifically, nutraceuticals, beverages, food additives and beverage additives may be prepared by conventional manufacturing methods.
본 발명에서 건강기능식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체중조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다.In the present invention, a health functional food is a biological defense rhythm control, disease prevention and the like having a food group or a food composition which has added value to the food by using physical, biochemical, biotechnological techniques, etc. It refers to a food that is designed and processed to fully express the weight control function related to recovery.
상기 건강기능식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강기능식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다. The dietary supplement may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of dietary supplements.
본 발명에서 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 건강기능음료를 포함하는 의도이다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 헛개나무 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In the present invention, the drink refers to a generic term for drinking to quench thirst or to enjoy the taste and is intended to include a functional beverage. The beverage is not particularly limited to other ingredients other than including the hawthorn extract as an active ingredient in the indicated ratio as an active ingredient, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have.
상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and Sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
상기 천연 탄수화물의 비율은 본 발명의 식품 조성물 100 ㎖ 당 일반적으로 약 1 g 내지 20g, 바람직하게는 5 g 내지 12 g일 수 있다. 그 밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.The ratio of the natural carbohydrate may generally be about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the food composition of the present invention. In addition, the composition of the present invention may further contain a pulp for the production of natural fruit juices, fruit juice drinks, vegetable drinks.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 헛개나무 추출물 100 중량부 당 0 내지 2,000 중량부 범위에서 선택될 수 있다.These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 2,000 parts by weight per 100 parts by weight of the bark of the present invention.
본 발명에서 건강기능음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다. In the present invention, the health functional beverage is a biological defense rhythm control or disease prevention of a beverage group or beverage composition which has added value to the beverage by using physical, biochemical and biotechnological techniques to act and express the function of the beverage for a specific purpose. Means a beverage that is designed and processed to fully express the gymnastic function related to recovery and the like.
상기 건강기능음료는 지시된 비율로 필수 성분으로서 본 발명의 헛개나무 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health functional beverage is not particularly limited to other ingredients except for containing the hawthorn extract of the present invention as an essential ingredient in the ratio indicated, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. .
상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 g 내지 20 g, 바람직하게는 5 g 내지 12 g이다.Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and xylitol Sugar alcohols such as sorbitol and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention.
또한, 헛개나무 추출물을 유효성분으로 포함하는 장 질환, 일 예로 변비 예방 또는 개선용 식품 조성물에 있어서, 상기 유효성분은 전체 식품 중량의 0.01 중량% 내지 15 중량%로 포함할 수 있으며, 음료 조성물은 100 ㎖를 기준으로 0.02 g 내지 5 g, 바람직하게는 0.3 g 내지 1 g의 비율로 포함할 수 있다.In addition, in the intestinal disease, for example, constipation prevention or improvement food composition comprising the extract of the bark as an active ingredient, the active ingredient may comprise from 0.01% to 15% by weight of the total food weight, the beverage composition It may be included in a ratio of 0.02 g to 5 g, preferably 0.3 g to 1 g based on 100 ml.
또한, 본 발명은 상기 목적을 달성하기 위하여, 헛개나무(Hovenia dulcis) 추출물의 용도에 관한 것이다.The present invention also relates to the use of Hovenia dulcis extract in order to achieve the above object.
상기 헛개나무 추출물의 용도는 장 질환과 관련된 용도, 구체적으로 장 질환의 치료, 개선 또는 예방을 위한 용도일 수 있다. 구체적으로, 변비 치료 또는 예방용 용도나 변비 개선 또는 예방용 용도일 수 있다.The use of the bark extract may be used for intestinal diseases, specifically for the treatment, improvement or prevention of intestinal diseases. Specifically, it may be used for treating or preventing constipation or improving or preventing constipation.
상기 장 질환은 장 활동 이상에 의해 발생되는 모든 질환을 포함하는 의미로, 구체적으로 변비, 설사, 게실염, 설사변비교대증 및 과민성 대장증후군으로 이루어진 군 중에서 선택된 어느 하나, 더욱 구체적으로 변비일 수 있다.The intestinal disease is a meaning including all diseases caused by abnormal bowel activity, specifically, one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea altered bowel syndrome and irritable bowel syndrome, more specifically constipation.
상기 변비는 기능성 변비 또는 기질성 변비일 수 있고, 상기 기능성 변비는 이완성 변비, 경련성 변비 또는 배변 장애성 변비일 수 있으며, 상기 기질성 변비는 기능성 변비 장관의 협착, 긴 S상 결장증 또는 거대 결장증일 수 있다The constipation may be a functional constipation or a matrix constipation, the functional constipation may be a laxative constipation, convulsive constipation or a bowel movement constipation, the temporal constipation is stenosis of the functional constipation intestinal tract, long S-phase colon or giant colon May be
상기 헛개나무 추출물은 추출용매로 추출하거나 추출용매로 추출하여 제조한 조추출물에 분획용매를 가하여 분획하여 제조할 수 있다.The bark extract may be prepared by adding a fractional solvent to the crude extract prepared by extracting or extracting with an extraction solvent.
상기 추출용매는 물 및 유기용매로 이루어진 군에서 선택된 1종 이상일 수 있고, 일 예로 물일 수 있다. 상기 유기용매는 메탄올, 에탄올 등의 탄소수 1 내지 5의 알코올, 에틸아세테이트 또는 아세톤 등의 극성용매와 에테르, 클로로포름, 벤젠, 헥산 또는 디클로로메탄의 비극성용매 또는 이들의 혼합용매일 수 있다.The extraction solvent may be at least one selected from the group consisting of water and an organic solvent, for example, may be water. The organic solvent may be a polar solvent such as alcohol having 1 to 5 carbon atoms such as methanol or ethanol, ethyl acetate or acetone, and a nonpolar solvent of ether, chloroform, benzene, hexane or dichloromethane, or a mixed solvent thereof.
상기 탄소수 1 내지 5의 알코올은 알코올 또는 알코올 수용액일 수 있고, 구체적으로 50% 내지 99%의 에탄올 등의 탄소수 1 내지 5의 알코올 수용액일 수 있으며, 더욱 구체적으로 50% 내지 95% 에탄올 등의 탄소수 1 내지 5의 알코올 수용액일 수 있다.The alcohol having 1 to 5 carbon atoms may be an alcohol or an aqueous alcohol solution, and specifically, may be an aqueous alcohol solution having 1 to 5 carbon atoms such as 50% to 99% ethanol, and more specifically 50 to 95% carbon atoms such as ethanol. It may be 1 to 5 aqueous alcohol solution.
상술한 바와 같이, 본 발명의 헛개나무 추출물은 활성탄(charcoal)을 이용한 동물 모델, 변비유발 실험모델 및 장 운동능력 실험모델에서 장기능 활성을 유도하고, 장내의 점액 분비를 활성화하여 변비 개선에 탁월한 효과를 가질 뿐만 아니라 식품으로 식용하던 식물인 천연물질 유래의 것으로 부작용이나 독성의 문제가 발생될 가능성이 적으므로, 본 발명은 장 기능 개선 및 장 질환, 구체적으로 변비의 개선, 예방 및 치료에 효과적이고 안전한 의약 조성물 또는 기능성 식품 조성물로 사용될 수 있으므로, 본 발명은 산업적으로 다양하게 사용될 수 있다.As described above, the bark extract of the present invention induces intestinal function activity in the animal model using charcoal, constipation-induced experimental model and intestinal motility experimental model, and activates the mucous secretion in the intestine, which is excellent for improving constipation. In addition to having an effect, it is derived from a natural substance that is a plant edible as a food, so it is less likely to cause side effects or toxicity problems. Therefore, the present invention is effective in improving intestinal function and intestinal diseases, specifically constipation, prevention and treatment. Since the present invention can be used as a safe and safe pharmaceutical composition or a functional food composition, the present invention can be used in various industries.
도 1은 본 발명의 일 실시예에 따른 헛개나무 추출물의 추출물 및 분획물을 제조하는 개략도이다.Figure 1 is a schematic diagram for preparing the extract and fractions of the bark tree extract according to an embodiment of the present invention.
도 2는 본 발명의 일 실시예에 따른 헛개가지 추출물을 변비가 유발된 동물모델에 시료 투여 3일 동안 수거한 변의 수를 대조군과 비교하여 나타낸 그래프이다.Figure 2 is a graph showing the number of stool collected during the three days of sample administration to the constipation-induced constipation-derived animal model according to an embodiment of the present invention compared to the control.
도 3은 본 발명의 일 실시예에 따른 헛개가지 추출물을 변비가 유발된 동물모델에 시료 투여 3일 동안 수거한 변의 수를 백분율%로 대조군과 비교하여 나타낸 그래프이다.Figure 3 is a graph showing the number of stool collected during the three days of sample administration to the constipation-induced constipation-derived animal extract according to an embodiment of the present invention as a percentage (%).
도 4는 본 발명의 일 실시예에 따른 헛개가지 추출물의 변비개선효과 관찰 실험에서 시료 투여 3일 동안 수거한 변의 무게를 대조군과 비교하여 나타낸 그래프이다.Figure 4 is a graph showing the weight of the stool collected during the three days of the administration of the sample in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention compared to the control.
도 5는 본 발명의 일 실시예에 따른 헛개가지 추출물의 변비개선효과 관찰 실험에서 시료 투여 3일 동안 수거한 변의 무게를 백분율%(도 3b)로 대조군과 비교하여 나타낸 그래프이다.Figure 5 is a graph showing the weight of the stool collected during the three days of sample administration in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention compared to the control group in percentage (Fig. 3b).
도 6은 본 발명의 일 실시예에 따른 헛개가지 추출물의 변비개선효과 관찰 실험에서 시료 투여 3일 동안 수거한 변의 수분함량을 대조군과 비교하여 나타낸 그래프이다.Figure 6 is a graph showing the water content of the stool collected for 3 days of sample administration compared to the control in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention.
도 7은 본 발명의 일 실시예에 따른 헛개가지 추출물의 변비개선효과 관찰 실험에서 장내의 활성탄 식이(charcoal meal) 이동으로 나타낸 사진이다.7 is a photograph showing the movement of activated charcoal meal (charcoal meal) in the intestine in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention.
도 8는 본 발명의 일 실시예에 따른 헛개가지 추출물의 변비개선효과 관찰 실험에서 장관거리중 이동율(Rf)로 나타낸 그래프이다.8 is a graph showing the movement rate (Rf) in the intestinal tract in the constipation improvement effect observation experiment of the extract of the barley branch according to an embodiment of the present invention.
도 9 및 도 10은 본 발명의 일 실시예에 따른 헛개가지 추출물이 0.2mg/mL의 농도에서 대장의 수축이완 운동을 촉진하는 그래프를 대조군(도 9) 및 헛개나무 추출물 투여군(도 10)으로 나타낸 그래프이다.9 and 10 are graphs promoting the contractile relaxation exercise of the colon at a concentration of 0.2 mg / mL of the extract of the barley branch according to an embodiment of the present invention as a control group (Fig. 9) and the bark tree extract administration group (Fig. 10) The graph shown.
이하, 본 발명의 이해를 돕기 위하여 구체적인 실시예 및 비교예를 통하여 본 발명의 구성 및 효과를 보다 상세히 설명하기로 한다. 그러나, 하기 실시예는 본 발명을 보다 명확하기 이해시키기 위한 것일 뿐이며, 본 발명의 권리범위가 하기 실시예에 의해 한정되는 것은 아니고, 특허청구범위에 의하여 해석되어야 하며, 그와 동등한 범위 내에 있는 모든 기술 사상은 본 발명의 권리범위에 포함되는 것으로 해석되어야 한다.Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to specific examples and comparative examples in order to help understanding of the present invention. However, the following examples are only intended to more clearly understand the present invention, the scope of the present invention is not limited by the following examples, should be interpreted by the claims, all equivalent within the scope The technical idea should be construed as being included in the scope of the present invention.
실시예 1. 헛개가지 추출물 및 분획물의 제조Example 1. Preparation of Barley Branch Extract and Fractions
실시예 1-1. 헛개가지 추출물의 제조Example 1-1. Preparation of Barley Branch Extract
헛개가지 1 kg을 증류수로 수세한 다음 증류수 20 L를 가하고, 전기약탕기로 100℃에서 3시간 동안 가열, 추출하였다. 400 메쉬 여과포로 여과한 다음 감압회전농축기로 농축하였다. 여과 후 남은 잔사에 다시 동량의 증류수를 사용하여 동일 과정으로 2 번 더 추출, 여과 및 감압 농축한다. 농축된 열수추출물을 온풍건조 또는 동결건조기(Freeze dryer) -40℃에서 48시간 건조시켜 본 발명의 헛개가지 열수추출물 47 g(이하, WEHD이라 함)을 얻어 각각 하기 실험예의 시료로 사용하였다.1 kg of barley branch was washed with distilled water, 20 L of distilled water was added thereto, and heated and extracted at 100 ° C. for 3 hours using an electric water bath. The filtrate was filtered through a 400 mesh filter cloth and concentrated under reduced pressure. After filtration, the remaining residue was extracted, filtered and concentrated under reduced pressure two more times using the same amount of distilled water. The concentrated hot water extract was dried for 48 hours at -40 ° C. in a warm air dryer or freeze dryer to obtain 47 g of the waste hot water extract of the present invention (hereinafter referred to as WEHD), respectively, as a sample of the following experimental example.
실시예 1-2. 헛개가지 분획물의 제조Example 1-2. Preparation of Flaty Fraction
증류수 1 L에 완전히 용해시킨 후 분획 여두에 넣고 Hexane 1 L를 첨가하여 water층과 hexane층을 분리하였고 이와 같은 공정을 3번 반복하였다. 동일한 과정을 통해 클로로포름(chloroform), 에틸아세테이트(ethylacetate), 부탄올(butanol)을 순차적으로 가하여 각 분획물을 얻었고, 얻어진 각각의 분획물을 감압여과 장치로 여과하여 농축한 후 동결 건조하여 용매를 완전히 제거한 뒤 본 실험에 사용하였다. After completely dissolving in 1 L of distilled water, the mixture was added to a fractional filter, and 1 L of Hexane was added to separate the water layer and the hexane layer. The same process was repeated three times. Through the same process, chloroform, ethylacetate, and butanol were added sequentially to obtain each fraction. Each of the obtained fractions was concentrated by filtration through a vacuum filter, and then freeze-dried to completely remove the solvent. It was used for this experiment.
실시예 1-2-1. 헥산 가용성 분획 분리Example 1-2-1. Hexane Soluble Fraction Separation
실시예 1의 헛개가지 열수추출물 40g을 lL의 증류수에 완전히 용해시킨 후에 분획여두에 넣고 헥산 1L를 첨가하여 헥산 불용성층(수층)과 헥산가용성층을 분리하였다. 다시 헥산 불용성층(수층)을 대상으로 동일한 공정을 3번 반복하여 헥산 불용성 분획물 및 가용성 분획물을 수집하였다. After dissolving 40 g of vaccinated hot water extract of Example 1 in 1 liter of distilled water, the mixture was put into a fractional filter and 1L of hexane was added to separate the hexane-insoluble layer (aqueous layer) and the hexane-soluble layer. Again, the same process was repeated three times on the hexane insoluble layer (aqueous layer) to collect the hexane insoluble fraction and the soluble fraction.
실시예 1-2-2. 클로로포름 가용성 분획분리Example 1-2-2. Chloroform Soluble Fractionation
헥산불용성 분획(수층)에 클로로포름 1 L를 가하여 섞은 후에 클로로포름가용성 분획 및 불용성 분획을 분리하였고, 클로로포름 불용성층(수층)을 대상으로 동일한 공정을 3번 반복하여 클로로포름 불용성 분획물 및 가용성 분획물을 수집하였다.After adding 1 L of chloroform to the hexane insoluble fraction (aqueous layer), the chloroform soluble fraction and the insoluble fraction were separated, and the same process was repeated three times on the chloroform insoluble layer (aqueous layer) to collect the chloroform insoluble fraction and the soluble fraction.
실시예 1-2-3. 에틸아세테이트 가용성 분획분리Example 1-2-3. Ethyl acetate soluble fractionation
클로로포름 불용성 분획(수층)에 에틸아세테이트 1 L를 가하여 섞은 후에 에틸아세테이트 가용성 분획 및 불용성 분획을 분리하였고, 에틸아세테이트 불용성층(수층)을 대상으로 동일한 공정을 3번 반복하여 에틸아세테이트 불용성 분획물 및 가용성 분획물을 수집하였다.After adding 1 L of ethyl acetate to the chloroform insoluble fraction (aqueous layer), the ethyl acetate soluble fraction and the insoluble fraction were separated, and the same process was repeated three times for the ethyl acetate insoluble layer (aqueous layer). Was collected.
실시예 1-2-4. 부탄올 가용성 분획분리Example 1-2-4. Butanol Soluble Fractionation
상기 에틸아세테이트 불용성 분획(수층)에 부탄올 1 L를 가하여 섞은 후에 부탄올 가용성 분획 및 불용성 분획을 분리하였고, 부탄올 불용성층을 대상으로 동일한 공정을 3번 반복하여 부탄올 불용성 분획물 및 가용성 분획물을 수집하였다.1 L of butanol was added to the ethyl acetate insoluble fraction (aqueous layer), followed by mixing. The butanol soluble fraction and the insoluble fraction were separated, and the butanol insoluble fraction and the soluble fraction were collected by repeating the same process three times.
상기 헥산 가용성 분획, 클로로포름 가용성 분획, 에틸아세테이트 가용성 분획 및 부탄올 가용성 분획을 감압 농축한 후에 동결 건조하여 헥산분획물 0.04 g, 클로로포름 분획물 0.6 g, 에틸아세테이트 분획물 2.2 g, 부탄올 분획물 8 g, 물 분획물 18.35 g을 얻어 시료로 사용하였다.The hexane soluble fraction, the chloroform soluble fraction, the ethyl acetate soluble fraction and the butanol soluble fraction were concentrated under reduced pressure, and then freeze-dried to obtain hexane fraction 0.04 g, chloroform fraction 0.6 g, ethyl acetate fraction 2.2 g, butanol fraction 8 g, and water fraction 18.35 g. Was obtained and used as a sample.
실시예 2 변비유발 실험 모델에서 헛개가지 추출물의 변비 치료효과 확인 Example 2 Confirmation of the Constipation Treatment Effect of Barley Branches Extract in Constipation-Induced Experimental Model
상기 실시예 1에서 얻은 헛개 추출물의 변비 치료효과를 측정하기 위하여 랫트 모델을 이용하여 문헌에 개시된 방법을 응용하여 하기와 같이 실험을 실시하였다(Mamoru kakino et al., Laxative effects of agarwood on low-fiber diet-induced constipation in rats. BMC Complementary and alternative Medicine. 2010; 10:68).In order to measure the constipation therapeutic effect of the extract of the hut obtained in Example 1, the experiment was conducted using the method described in the literature using a rat model as follows (Mamoru kakino et al., Laxative effects of agarwood on low-fiber diet-induced constipation in rats.BMC Complementary and alternative Medicine.2010; 10:68).
실시예 2-1. 실험동물의 사육Example 2-1. Breeding of Experimental Animals
4주령(체중 100 g 내지 200 g)의 Sprague-Dawley 수컷 흰쥐를 (주)샘타코에서 구입하여, 1주일간 환경에 적응시킨 후 실험에 사용하였다. 사육환경은 온도 20℃ 내지 22℃ 습도 50% 내지 55%이었으며, 명암주기는 12시간 단위로 조절되었다. 물과 사료는 자유로이 공급시켰다. 실험동물은 난괴법을 이용하여 5마리씩 5개의 군으로 분리하여, 정상군으로 일반식이 사료를 섭취하는 군(Normal group), 음성대조군으로 저 식이섬유 사료(low fiber diet, LFD) 섭취군(이하, LFD이라 함), 양성대조군으로 변비치료제 약물인 둘코락스(dulcolax; 베링거 인겔하임) 투여군(이하, LFD + dulcolax이라 함), 헛개가지 열수 추출물(WEHD, 200 mg/kg) 투여군(이하, LFD + WEHD이라 함)으로 각각 나누었다. 실험은 정상대조군에 정상사료만을 공급하였으며, 음성대조군, 양성대조군, 헛개가지 추출물 투여군은 low fiber diet를 공급하였다. Sprague-Dawley male rats of 4 weeks old (100 g to 200 g body weight) were purchased from Samtaco Co., Ltd. and used for experiments after being adapted to the environment for 1 week. The breeding environment was a temperature of 20 ℃ to 22 ℃ humidity 50% to 55%, the contrast cycle was adjusted by 12 hours. Water and feed were freely provided. The experimental animals were divided into five groups of five by using the ingot method, and were fed a normal diet as a normal group (Normal group) and a negative control group as a low fiber diet (LFD) intake group (hereinafter , LFD), Dulcolax (Dercolax; Boehringer Ingelheim), a positive control group (hereinafter referred to as LFD + dulcolax), HTH (200 mg / kg) treated group (hereinafter, LFD) + WEHD). In the experiment, only normal feed was supplied to the normal control group, and the negative control group, the positive control group, and the barley extract administration group were fed the low fiber diet.
저 식이섬유 사료(low fiber diet, LFD)를 제조하여 변비를 유발하였으며, 조성은 하기와 같다. 수분은 9.0%, 조단백질은 21.9%, 조지방은 6.1%, 식이섬유는 0.1%, 조회분은 5.9%, 가용성 무질소물은 57.0%을 함유하고 있으며, 조성은 옥수수 전분 41.5%, 우유 카제인 24.5%, 슈크로오스 10.0%, 덱스트린 10.0%, 미네랄 혼합물 7.0%, 옥수수 오일 6.0%, 비타민 혼합물 1.0%이다. Low fiber diet (LFD) was produced to cause constipation, the composition is as follows. It contains 9.0% of moisture, 21.9% of crude protein, 6.1% of crude fat, 0.1% of dietary fiber, 5.9% of crude starch, and 57.0% of soluble nitrogen.The composition is 41.5% of corn starch and 24.5% of milk casein. , 10.0% sucrose, 10.0% dextrin, 7.0% mineral mixture, 6.0% corn oil, 1.0% vitamin mixture.
변비 치료효과를 확인하기 위하여 28일 동안 변비를 유발시킨 후, 정상대조군과 음성대조군은 증류수를 경구투여 하였고, 양성대조군으로는 삼투성 약물인 둘코락스(dulcolax)를 100 mg/kg의 농도로, 실험군으로 헛개가지 열수추출물(WEHD)을 200 mg/kg의 농도로 1일 1회씩 경구투여 하였다. 각 실험동물의 변은 실험시작 후 3일간 매일 수거하였으며, 개체 당 변의 개수와 변 중량(wet weight)을 측정하였다. 상기 변을 오븐에서 24시간 동안 건조시켜 건 중량을 측정하고, 변 중량과 건 중량의 차이를 변 중량으로 나누어 계산하였다. 이를 통하여 헛개가지 열수추출물의 변비 치료 효과를 관찰하였다.After constipation was induced for 28 days to confirm the treatment effect of constipation, the normal control group and the negative control group were orally administered distilled water, and the positive control group was osmolal drug dulcolax (dulcolax) at a concentration of 100 mg / kg Experimental group was administered orally once a day with a hot water extract (WEHD) at a concentration of 200 mg / kg. The stools of each experimental animal were collected daily for 3 days after the start of the experiment, and the number of stools and the weight of the stool (wet weight) were measured. The sides were dried in an oven for 24 hours to determine the dry weight, and the difference between the side weight and the dry weight was calculated by dividing the side weight. In this study, the effect of constipation treatment on the hot-water extract of the barley branch was observed.
실시예 2-2. 변비유발 실험 모델에서 헛개가지 추출물의 변비 치료효과 확인 Example 2-2. Confirmation of Constipation's Treatment Effect of Barley Branch Extract in Constipation-Induced Experimental Model
실험 결과, 변비 유도 실험동물 모델에 대해 실시예 1에서 추출한 헛개가지 추출물의 변비의 치료효과를 확인하였으며, 각 군의 변의 수, 무게, 수분함량은 음성대조군과 비교하여, 그 결과를 도 2 내지 도 6에 나타내었다.As a result, the constipation-induced experimental animal model confirmed the therapeutic effect of the constipation of the extract of barley branch extract extracted in Example 1, the number, weight, and water content of each group compared to the negative control group, the results are shown in Figure 2 to 6 is shown.
상기 도 2 내지 도 6에 나타낸 바와 같이, 저 식이사료로 28일 동안 변비를 유도한 결과 변의 수는 음성대조군이 일반식이 투여한 정상대조군에 비해 57% 급격히 감소하였다. 하지만 변비 유발 후 3일 동안 헛개가지 추출물을 투여한 군에서 변비의 지연이 관찰되었다. 특히 헛개가지 추출물 200 mg/kg을 투여한 군은 음성대조군에 비하여 변의 수가 30% 증가한 것을 확인할 수 있었다.As shown in FIG. 2 to FIG. 6, as a result of inducing constipation for 28 days with low diet, the number of stools decreased 57% sharply compared to the normal control group administered with the normal diet. However, delayed constipation was observed in the group administered with the barley extract for 3 days after the induction of constipation. In particular, the group administered with 200 mg / kg of halibut extract was confirmed that the number of stools increased by 30% compared to the negative control group.
또한, 상기 도 4 및 도 5에 나타낸 바와 같이, 각 군의 변을 3일 동안 수거하여 건조한 변의 무게가 음성대조군에 비하여 헛개가지 추출물 투여 군이 7.1% 증가하는 것을 확인하였다. 또한 상기 도 6에 나타낸 바와 같이, 수분함량에서도 헛개가지 추출물을 투여한 군이 음성대조군보다 5% 증가하는 것을 확인하였다.In addition, as shown in FIG. 4 and FIG. 5, the sides of each group was collected for 3 days, and the weight of the dry side was increased by 7.1% compared to the negative control group compared to the negative control group. In addition, as shown in FIG. 6, even in the moisture content, the group administered with the barley branch extract was confirmed to increase by 5% than the negative control group.
실시예 3 헛개가지 열수추출물의 활성탄 식이 이동(charcoal meal transit)에 대한 효과Example 3 Effects of Charcoal Meal Transit on the Bare Water Extract
장기능 개선 및 변비개선 효과를 평가하기 위해 활성탄 식이(charcoal meal) 이동 실험을 수행하였다. 헛개가지 열수 추출물(WEHD)을 농도 200 mg/kg로 경구투여 하고, 1시간 후 실험동물에게 10% 아라비아고무(arabic gum, Sigma사, 미국)용액(0.2 ml/동물 p.o)에 용해된 5% 활성탄(Sigma사, 미국) 현탁액을 투여하였다. 1시간 뒤 희생시켜 위장관을 적출하여 십이지장에서부터 회장까지의 장관거리중 이동율(Rf)을 조사하여, 도 7 및 도 8에 나타내었다.Activated charcoal meal transfer experiments were performed to evaluate the effects of bowel function and constipation. Tortilla water extract (WEHD) was orally administered at a concentration of 200 mg / kg, and 1 hour later, 5% dissolved in 10% arabic gum (Sigma, USA) solution (0.2 ml / animal po) to the test animals. Activated carbon (Sigma, USA) suspensions were administered. After 1 hour, the gastrointestinal tract was sacrificed, and the migration rate (Rf) in the intestinal distance from the duodenum to the ileum was examined, and is shown in FIGS. 7 and 8.
본 실험에 사용한 활성탄(activated carbon)은 다양한 유기물질(목재 등)을 태워서 제조한 것으로, 흡착성이 강하고 무독성이며, 약리효능이 없는 물질이다. Activated carbon used in this experiment was produced by burning various organic materials (wood, etc.), and has a strong adsorption, nontoxicity, and no pharmacological effect.
실험결과, 도 7 및 도 8에 나타낸 바와 같이, 식수만 공급한 대조군에 비하여 헛개가지 열수 추출물 투여군의 활성탄 식이 이동성이 증가한 것을 확인하였다. 특히, 대조군과 비교하여 십이지장에서부터 회장까지의 장관거리중 이동율(Rf)이 5.6% 증가한 것을 확인할 수 있었다.As a result of the experiment, as shown in Figures 7 and 8, it was confirmed that the mobility of the activated carbon diet of the barley hot water extract administration group compared to the control group fed only drinking water. In particular, it was confirmed that the rate of movement (Rf) in the intestinal distance from duodenum to ileum increased by 5.6% compared to the control group.
실시예 4. 헛개가지 열수추출물의 적출 회장의 운동성에 대한 전기생리학적 효과 측정Example 4 Measurement of the Electrophysiological Effect on the Motility of Extracted Ventricle of the Extravaginal Hot Water Extract
체중 300 g 내지 350 g의 흰쥐를 CO2에 의하여 희생시키고 복부를 정중 절개하여 회장을 분리 적출한 다음, Kreb's 용액(111 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 2.0 mM CaCl2, 1.2 mM NaH2PO4, 25 mM NaHCO3, 11.5 mM glucose) 내에서 2 cm의 절편을 만들어 사용하였다. 회장 절편은 산소로 포화시킨 Kreb's 용액으로 채운 아크릴 수조 내에 현수하였다. 아크릴 수조 내의 온도는 37℃로 유지하였으며 실험이 진행되는 동안 계속 carbogen(95% O2 및 5% CO2)을 공급하여 용액의 pH를 7.4로 유지시켰다. 회장절편에 0.5 g의 resting tension을 준 후 15분마다 Kreb's 용액을 바꾸어 주면서 1시간 동안 안정화시켰다. 회장절편의 수축이완 반응은 고정된 절편의 다른 한쪽을 등척성 장력 측정기(isometric force-displacement transducer, FT03, Grass, AD instruments, Colorado spring, Co., USA)에 연결시켜 physiograph recorder(Powerlab/400, AD instruments)로 기록하고 Chart 4 for Windows program(AD instruments)으로 분석하였다. 적출 회장 절편의 기본 장력에 미치는 헛개가지 열수추출물의 효과는 회장 절편의 운동성이 안정화 되어 그 장력이 일정하게 유지되면 헛개가지 열수추출물을 0.2 mg/mL 의 농도로 첨가하여 장력의 변화에 따른 진폭을 측정하여, 그 결과를 도 9 및 도 10에 나타내었다. Rats weighing 300 g to 350 g were sacrificed by CO 2 , the abdomen was incised and the ileum was isolated and separated, followed by Kreb's solution (111 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 2.0 mM CaCl 2 , 1.2 mM). 2 cm fragments were used in NaH 2 PO 4 , 25 mM NaHCO 3 , 11.5 mM glucose). The ileal sections were suspended in an acrylic bath filled with Kreb's solution saturated with oxygen. The temperature in the acrylic bath was maintained at 37 ° C. and the pH of the solution was maintained at 7.4 by continuously supplying carbogen (95% O 2 and 5% CO 2 ) during the experiment. 0.5 g of resting tension was applied to the ileum sections, and then stabilized for 1 hour while changing Kreb's solution every 15 minutes. The contractile relaxation response of the ileal section is connected to an isometric force-displacement transducer (FT03, Grass, AD instruments, Colorado spring, Co., USA) by connecting the other side of the fixed section to a physiograph recorder (Powerlab / 400, AD). instruments) and analyzed by Chart 4 for Windows program (AD instruments). The effect of the barley hot water extract on the basic tension of the extracted ileal section is that when the motility of the ileal section is stabilized and the tension is kept constant, the barley hot water extract is added at a concentration of 0.2 mg / mL to change the amplitude according to the tension change. It measured and the result is shown to FIG. 9 and FIG.
상기 도 9 및 도 10에 나타낸 바와 같이, 헛개가지 추출물이 장 운동에 영향을 주는 것으로 확인되었다. 즉, 회장절편에 0.5 g의 resting tension을 준 후 15분마다 Kreb's 용액을 바꾸어 주면서 1시간 동안 안정화시킨 후, 헛개가지 열수추출물을 0.2 mg/mL 의 농도에서 대장의 수축 이완반응을 시킴으로서 장 운동능력 효과를 나타내었다. 이상의 결과는 실험동물에서 보여주었던 헛개가지 추출물의 변비 개선효과가 장의 운동성 증가와 관련이 있음을 보여준다.As shown in FIG. 9 and FIG. 10, it was confirmed that the barley branch extract affects bowel movement. In other words, 0.5 g of resting tension was applied to the ileum section, and then stabilized for 1 hour while changing the Kreb's solution every 15 minutes, and the bowel hot water extract was subjected to bowel contraction relaxation at a concentration of 0.2 mg / mL. The effect was shown. The above results show that the constipation-improving effect of the barley branch extract showed in laboratory animals is associated with increased intestinal motility.
제조예. 건강기능식품의 제조 Preparation example. Preparation of health functional food
헛개나무 가지 추출물 분말 1,000 ㎎Green Tree Branch Extract Powder 1000mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎ Vitamin C 10 mg
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍Folate 50 ㎍
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산 제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium Citrate 90 mg
탄산칼슘 100 ㎎ Calcium Carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is a composition which is relatively suitable for the health functional food, the composition is mixed in a preferred embodiment, but the compounding ratio may be arbitrarily modified, and the above components are mixed according to a general health functional food manufacturing method. The granules can then be prepared and used in the manufacture of nutraceuticals in accordance with conventional methods.

Claims (8)

  1. 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 장 질환 치료 또는 예방용 조성물.A composition for the treatment or prevention of bowel disease, comprising the extract of Hovenia dulcis as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 헛개나무 추출물은 헛개나무 가지에 대해 물, 탄소수 1 내지 5의 알코올 및 이들의 혼합물로 이루어진 군 중에서 선택된 어느 하나를 추출용매로 추출한 것인 장 질환 치료 또는 예방용 조성물.Wherein the bark tree extract is a composition for treating or preventing intestinal diseases is extracted from any one selected from the group consisting of water, alcohol having 1 to 5 carbon atoms and mixtures thereof with respect to the bark tree branches.
  3. 제2항에 있어서,The method of claim 2,
    상기 헛개나무 추출물은 상기 헛개나무 가지 추출물에 헥산, 메틸렌클로라이드, 아세톤, 에틸아세테이트, 에틸에테르, 클로로포름, 부탄올 물 및 이들의 혼합물로 이루어진 군으로부터 선택된 어느 하나를 분획용매로 분획한 헛개나무 추출물의 분획물인 장 질환 치료 또는 예방용 조성물.The holly tree extract is a fraction of holly tree extract obtained by fractionating any one selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, butanol water, and mixtures thereof Composition for treating or preventing intestinal diseases.
  4. 제1항에 있어서,The method of claim 1,
    상기 장 질환은 변비, 설사, 게실염, 설사변비교대증 및 과민성 대장증후군으로 이루어진 군 중에서 선택된 어느 하나인 장 질환 치료 또는 예방용 조성물.The bowel disease is any one selected from the group consisting of constipation, diarrhea, diverticulitis, diarrhea constipation and irritable bowel syndrome composition for the treatment or prevention of bowel disease.
  5. 제4항에 있어서,The method of claim 4, wherein
    상기 장 질환은 변비인 장 질환 치료 또는 예방용 조성물.The bowel disease is a constipation for treating or preventing bowel disease composition.
  6. 제5항에 있어서,The method of claim 5,
    상기 변비는 기능성 변비 또는 기질성 변비인 장 질환 치료 또는 예방용 조성물.The constipation is a functional constipation or organic constipation composition for the treatment or prevention of bowel disease.
  7. 제6항에 있어서,The method of claim 6,
    상기 기능성 변비는 이완성 변비, 경련성 변비 또는 배변 장애성 변비이고, 상기 기질성 변비는 기능성 변비 장관의 협착, 긴 S상 결장증 또는 거대 결장증인 장 질환 치료 또는 예방용 조성물.The functional constipation is a laxative constipation, constipation constipation or bowel movement constipation, the organic constipation is a constipation of the functional constipation intestinal tract, elongated S or colon colon composition for the treatment or prevention of bowel disease.
  8. 헛개나무(Hovenia dulcis) 추출물을 유효성분으로 포함하는 변비 예방 또는 개선용 식품 조성물.Food composition for preventing or improving constipation comprising the extract of Hovenia dulcis as an active ingredient.
PCT/KR2012/008138 2011-11-24 2012-10-08 Composition comprising hovenia dulcis extract for treating or preventing intestinal disorders WO2013077542A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0123444 2011-11-24
KR20110123444 2011-11-24

Publications (1)

Publication Number Publication Date
WO2013077542A1 true WO2013077542A1 (en) 2013-05-30

Family

ID=48469952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/008138 WO2013077542A1 (en) 2011-11-24 2012-10-08 Composition comprising hovenia dulcis extract for treating or preventing intestinal disorders

Country Status (1)

Country Link
WO (1) WO2013077542A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100439012B1 (en) * 2001-03-29 2004-07-03 박근형 Antioxidants comprising extracts from the leaves and stems of hovenia dulcis thunb and process for separating extracts thereof
KR20060094296A (en) * 2005-02-24 2006-08-29 전명원 Kimchi Production Method Using the Extract of Bare Tree
KR20070089623A (en) * 2006-02-28 2007-08-31 동아제약주식회사 Extract of herbal and the composition containing the same
KR100901761B1 (en) * 2007-06-28 2009-06-11 (주)리즈바이오텍 The pharmaceutical composition and functional food containing extracts and fractions of Genus Hovenia for prevention and treatment of hepatitis B
KR20110069623A (en) * 2009-12-17 2011-06-23 고경원 Making method of hovenia dulcis juice

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100439012B1 (en) * 2001-03-29 2004-07-03 박근형 Antioxidants comprising extracts from the leaves and stems of hovenia dulcis thunb and process for separating extracts thereof
KR20060094296A (en) * 2005-02-24 2006-08-29 전명원 Kimchi Production Method Using the Extract of Bare Tree
KR20070089623A (en) * 2006-02-28 2007-08-31 동아제약주식회사 Extract of herbal and the composition containing the same
KR100901761B1 (en) * 2007-06-28 2009-06-11 (주)리즈바이오텍 The pharmaceutical composition and functional food containing extracts and fractions of Genus Hovenia for prevention and treatment of hepatitis B
KR20110069623A (en) * 2009-12-17 2011-06-23 고경원 Making method of hovenia dulcis juice

Similar Documents

Publication Publication Date Title
WO2015002391A1 (en) Composition having a function for alleviating premenstrual syndrome and menstrual pain
WO2020246777A1 (en) Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof
WO2016060426A1 (en) Composition containing dolichos lablab l. extract as active ingredient for preventing or alleviating non-alcoholic fatty liver diseases
WO2018174448A1 (en) Composition for treating and preventing climacteric syndrome containing combined herbal medicinal extract of white atractylis, mori fructus, chinese matrimony vine, longan, achyranthes, eucommia bark, and asparagus cochinchinensis merr. as active ingredient, and use of same
WO2013105693A1 (en) Pharmaceutical composition comprising extract from cortex of oryza sativa l. and hordeum vulgare var. hexastichon as active ingredient
WO2016153211A2 (en) Method for preparing citrus peel extract and composition for preventing, alleviating, or treating liver damage
WO2012134169A2 (en) Composition for lung cancer treatment and functional food containing gleditsiae semen extract
WO2013100340A1 (en) Composition comprising dendropanax morbiferus extract for improving male sexual function
WO2016190566A2 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
WO2017213306A1 (en) Composition for memory improvement comprising petasites japonicus leaf extract
WO2013141581A1 (en) Pharmaceutical composition or health food comprising lonicera coerulea var. edulis fruit extracts as active ingredients for preventing or improving ischemic cerebrovascular diseases
WO2017146486A1 (en) Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract
WO2020091265A1 (en) Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome
WO2016093613A2 (en) Composition for preventing or treating abnormal weight loss, containing citrus unshiu peel extract
US20240115644A1 (en) Composition for preventing, improving or treating gastritis or peptic ulcer comprising extract of cinnamomum cassia, fraction of said extract, isolate of said fraction or compounds isolated therefrom
WO2014073855A1 (en) Composition comprising natural substance extract or fraction thereof as active ingredient for preventing or treating acute renal failure
WO2014133276A1 (en) Composition containing, as active ingredients, menispermum dauricum, extract of menispermum dauricum, slime of menispermum dauricum, or extract of malt enzyme liquid of menispermum dauricum for preventing or treating anorexia
WO2018008973A1 (en) Composition comprising forsythiae fructus extract as effective ingredient for preventing, ameliorating or treating peripheral neuropathy
WO2013089429A1 (en) Composition for preventing or treating hyperlipidemia containing water extract of pleurotus eryngii var. ferulae as active ingredient
WO2017082501A1 (en) Composition for preventing or treating menopausal disorders, containing tetragonia tetragonoides (pall.) kuntze extract
KR102014922B1 (en) Composition for improving digestive functions comprising glabridin from Liquorice
WO2012105816A2 (en) Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof
WO2013077542A1 (en) Composition comprising hovenia dulcis extract for treating or preventing intestinal disorders
WO2011019153A2 (en) Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
KR20220067467A (en) A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12852386

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12852386

Country of ref document: EP

Kind code of ref document: A1